A new therapy developed by researchers holds promise for fight against type 1 and type 2 diabetes and can also be applied to treat autoimmune and inflammation-related diseases, a study has revealed.
Called Stem Cell Educator, in the therapy a patient’s blood is circulated through a closed-loop system that separates mononuclear cells by aphaeresis, briefly co-cultures them with CB-SCs, and returns the educated cells to the patient’s circulation.
The therapy is considered safe and effective as it helps remove abnormalities in multiple types of immune cells that contribute to the autoimmunity in type1 diabetes and the insulin resistance in type 2 diabetes.
“Current mechanistic studies demonstrated that platelets and their released mitochondria may contribute to the long-lasting clinical improvement of islet beta cell function in type 1 and 2 diabetic patients after Stem Cell Educator therapy,” said study lead author Dr Yong Zhao, an associated scientist at Hackensack University Medical Centre, US.
The study found improved metabolic control and reduced inflammation markers in subjects after receiving Stem Cell Educator therapy. Also, homeostasis model assessment (HOMA) of insulin resistance (HOMA-IR) demonstrated that insulin sensitivity was improved post treatment.
Moreover, mechanistic studies revealed that Stem Cell Educator therapy reverses immune dysfunctions through immune modulation on monocytes and balancing Th1/Th2/Th3 cytokine production.
The study was published in the journal STEM CELLS Translational Medicine (SCTM) recently.